Skip to main content

Table 2 Pretherapeutic Staging of 30 Patients with Indolent Lymphoma using WB-DWIBS/STIR and 18F-FDG-PET/CT

From: Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients

   Reference Staging*  
   Stage IE Stage II Stage III Stage IIIS Stage IIIE Stage IV Kappa [95% CI] §
WB-DWIBS/STIR (R1) Stage IE 10 0 0 0 0 0 0.96 [0.88–1.00]
Stage II 0 5 0 0 0 0
Stage III 0 0 6 0 0 0
Stage IIIS 0 0 1 2 0 0
Stage IIIE 0 0 0 0 1 0
Stage IV 0 0 0 0 0 5
WB-DWIBS/STIR (R2) Stage IE 10 0 0 0 0 0 0.96 [0.88–1.00]
Stage II 0 5 0 0 0 0
Stage III 0 0 6 0 0 0
Stage IIIS 0 0 1 2 0 0
Stage IIIE 0 0 0 0 1 0
Stage IV 0 0 0 0 0 5
18F-FDG-PET/CT (R1) Stage 0 1 0 0 0 0 0 0.92 [0.80–1.00]
Stage IE 9 0 0 0 0 0
Stage II 0 4 0 0 0 0
Stage III 0 0 7 0 0 0
Stage IIIS 0 1 0 2 0 0
Stage IIIE 0 0 0 0 1 0
Stage IV 0 0 0 0 0 5
18F-FDG-PET/CT (R2) Stage IE 10 0 0 0 0 0 0.96[0.88–1.00]
Stage II 0 4 0 0 0 0
Stage III 0 0 7 0 0 0
Stage IIIS 0 1 0 2 0 0
Stage IIIE 0 0 0 0 1 0
Stage IV 0 0 0 0 0 5
  1. §The pretherapeutic staging does not reflect bone marrow involvement of lymphoma
  2. *Data are numbers of patients. R1 = observer 1, R2 = observer 2, WB-DWIBS/STIR = whole-body diffusion-weighted imaging with background body signal suppression and T2-weighted short-tau inversion recovery magnetic resonance imaging, 18F-FDG-PET/CT = 18F-fluorodeoxyglucose-positron emission tomography-computed tomography